These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 38869519)
1. Development of Novel Tools for Dissection of Central Versus Peripheral Dopamine D2-Like Receptor Signaling in Dysglycemia. Bonifazi A; Ellenberger M; Farino ZJ; Aslanoglou D; Rais R; Pereira S; Mantilla-Rivas JO; Boateng CA; Eshleman AJ; Janowsky A; Hahn MK; Schwartz GJ; Slusher BS; Newman AH; Freyberg Z Diabetes; 2024 Sep; 73(9):1411-1425. PubMed ID: 38869519 [TBL] [Abstract][Full Text] [Related]
2. Development of novel tools for dissection of central versus peripheral dopamine D Bonifazi A; Ellenberger M; Farino ZJ; Aslanoglou D; Rais R; Pereira S; Mantilla-Rivas JO; Boateng CA; Eshleman AJ; Janowsky A; Hahn MK; Schwartz GJ; Slusher BS; Newman AH; Freyberg Z bioRxiv; 2024 Feb; ():. PubMed ID: 38529497 [TBL] [Abstract][Full Text] [Related]
3. New roles for dopamine D Farino ZJ; Morgenstern TJ; Maffei A; Quick M; De Solis AJ; Wiriyasermkul P; Freyberg RJ; Aslanoglou D; Sorisio D; Inbar BP; Free RB; Donthamsetti P; Mosharov EV; Kellendonk C; Schwartz GJ; Sibley DR; Schmauss C; Zeltser LM; Moore H; Harris PE; Javitch JA; Freyberg Z Mol Psychiatry; 2020 Sep; 25(9):2070-2085. PubMed ID: 30626912 [TBL] [Abstract][Full Text] [Related]
4. Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes. Tavares G; Marques D; Barra C; Rosendo-Silva D; Costa A; Rodrigues T; Gasparini P; Melo BF; Sacramento JF; Seiça R; Conde SV; Matafome P Mol Metab; 2021 Sep; 51():101241. PubMed ID: 33933677 [TBL] [Abstract][Full Text] [Related]
5. RalA employs GRK2 and β-arrestins for the filamin A-mediated regulation of trafficking and signaling of dopamine D2 and D3 receptor. Zheng M; Zhang X; Sun N; Min C; Zhang X; Kim KM Biochim Biophys Acta; 2016 Aug; 1863(8):2072-83. PubMed ID: 27188791 [TBL] [Abstract][Full Text] [Related]
6. Role of Dopamine D2/D3 Receptors in Development, Plasticity, and Neuroprotection in Human iPSC-Derived Midbrain Dopaminergic Neurons. Bono F; Savoia P; Guglielmi A; Gennarelli M; Piovani G; Sigala S; Leo D; Espinoza S; Gainetdinov RR; Devoto P; Spano P; Missale C; Fiorentini C Mol Neurobiol; 2018 Feb; 55(2):1054-1067. PubMed ID: 28092083 [TBL] [Abstract][Full Text] [Related]
7. Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake. Castro-Hernández J; Afonso-Oramas D; Cruz-Muros I; Salas-Hernández J; Barroso-Chinea P; Moratalla R; Millan MJ; González-Hernández T Neurobiol Dis; 2015 Feb; 74():325-35. PubMed ID: 25511804 [TBL] [Abstract][Full Text] [Related]
8. Current drug treatments targeting dopamine D3 receptor. Leggio GM; Bucolo C; Platania CB; Salomone S; Drago F Pharmacol Ther; 2016 Sep; 165():164-77. PubMed ID: 27343365 [TBL] [Abstract][Full Text] [Related]
9. Transient and rapid activation of Akt/GSK-3β and mTORC1 signaling by D3 dopamine receptor stimulation in dorsal striatum and nucleus accumbens. Salles MJ; Hervé D; Rivet JM; Longueville S; Millan MJ; Girault JA; Mannoury la Cour C J Neurochem; 2013 May; 125(4):532-44. PubMed ID: 23410496 [TBL] [Abstract][Full Text] [Related]
10. Chirality of Novel Bitopic Agonists Determines Unique Pharmacology at the Dopamine D3 Receptor. Adhikari P; Xie B; Semeano A; Bonifazi A; Battiti FO; Newman AH; Yano H; Shi L Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33924613 [TBL] [Abstract][Full Text] [Related]
13. Bromocriptine administration reduces hyperphagia and adiposity and differentially affects dopamine D2 receptor and transporter binding in leptin-receptor-deficient Zucker rats and rats with diet-induced obesity. Davis LM; Michaelides M; Cheskin LJ; Moran TH; Aja S; Watkins PA; Pei Z; Contoreggi C; McCullough K; Hope B; Wang GJ; Volkow ND; Thanos PK Neuroendocrinology; 2009; 89(2):152-62. PubMed ID: 18984941 [TBL] [Abstract][Full Text] [Related]
14. Unveiling the Differences in Signaling and Regulatory Mechanisms between Dopamine D Kim KM Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047716 [TBL] [Abstract][Full Text] [Related]
15. Targeting the dopamine D3 receptor: an overview of drug design strategies. Cortés A; Moreno E; Rodríguez-Ruiz M; Canela EI; Casadó V Expert Opin Drug Discov; 2016 Jul; 11(7):641-64. PubMed ID: 27135354 [TBL] [Abstract][Full Text] [Related]
16. Morphine alters the locomotor responses to a D2/D3 dopamine receptor agonist differentially in adolescent and adult mice. Hofford RS; Wellman PJ; Eitan S J Psychopharmacol; 2012 Oct; 26(10):1355-65. PubMed ID: 22522973 [TBL] [Abstract][Full Text] [Related]
17. Opposing relationships of BMI with BOLD and dopamine D2/3 receptor binding potential in the dorsal striatum. Cosgrove KP; Veldhuizen MG; Sandiego CM; Morris ED; Small DM Synapse; 2015 Apr; 69(4):195-202. PubMed ID: 25664726 [TBL] [Abstract][Full Text] [Related]
19. Pharmacological and Genetic Evidence of Dopamine Receptor 3-Mediated Vasoconstriction in Isolated Mouse Aorta. Zingales V; Torrisi SA; Leggio GM; Bucolo C; Drago F; Salomone S Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33799860 [TBL] [Abstract][Full Text] [Related]
20. Dopamine D3 receptor binding of (18)F-fallypride: Evaluation using in vitro and in vivo PET imaging studies. Mukherjee J; Constantinescu CC; Hoang AT; Jerjian T; Majji D; Pan ML Synapse; 2015 Dec; 69(12):577-91. PubMed ID: 26422464 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]